GMAB PE Ratio & Valuation,Is GMAB Overvalued

GMAB Relative Valuation

GMAB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, GMAB is overvalued; if below, it's undervalued.

Historical Valuation

Genmab A/S (GMAB) is now in the Fair zone, suggesting that its current forward PE ratio of 21.62 is considered Fairly compared with the five-year average of 38.81. The fair price of Genmab A/S (GMAB) is between 18.42 to 81.53 according to relative valuation methord.

Relative Value

Fair Zone

18.42-81.53

Current Price：31.35

Fair

21.87

8.08

EV/EBITDA

Genmab A/S. (GMAB) has a current EV/EBITDA of 8.08. The 5-year average EV/EBITDA is 28.07. The thresholds are as follows: Strongly Undervalued below -24.71, Undervalued between -24.71 and 1.68, Fairly Valued between 54.45 and 1.68, Overvalued between 54.45 and 80.84, and Strongly Overvalued above 80.84. The current Forward EV/EBITDA of 8.08 falls within the Historic Trend Line -Fairly Valued range.

9.16

EV/EBIT

Genmab A/S. (GMAB) has a current EV/EBIT of 9.16. The 5-year average EV/EBIT is 27.00. The thresholds are as follows: Strongly Undervalued below -9.53, Undervalued between -9.53 and 8.74, Fairly Valued between 45.27 and 8.74, Overvalued between 45.27 and 63.53, and Strongly Overvalued above 63.53. The current Forward EV/EBIT of 9.16 falls within the Historic Trend Line -Fairly Valued range.

4.58

Genmab A/S. (GMAB) has a current PS of 4.58. The 5-year average PS is 10.12. The thresholds are as follows: Strongly Undervalued below -1.17, Undervalued between -1.17 and 4.47, Fairly Valued between 15.76 and 4.47, Overvalued between 15.76 and 21.41, and Strongly Overvalued above 21.41. The current Forward PS of 4.58 falls within the Historic Trend Line -Fairly Valued range.

19.16

P/OCF

Genmab A/S. (GMAB) has a current P/OCF of 19.16. The 5-year average P/OCF is 32.60. The thresholds are as follows: Strongly Undervalued below -2.73, Undervalued between -2.73 and 14.93, Fairly Valued between 50.27 and 14.93, Overvalued between 50.27 and 67.93, and Strongly Overvalued above 67.93. The current Forward P/OCF of 19.16 falls within the Historic Trend Line -Fairly Valued range.

14.62

P/FCF

Genmab A/S. (GMAB) has a current P/FCF of 14.62. The 5-year average P/FCF is 37.50. The thresholds are as follows: Strongly Undervalued below 1.66, Undervalued between 1.66 and 19.58, Fairly Valued between 55.42 and 19.58, Overvalued between 55.42 and 73.34, and Strongly Overvalued above 73.34. The current Forward P/FCF of 14.62 falls within the Undervalued range.

Genmab A/S (GMAB) has a current Price-to-Book (P/B) ratio of 0.34. Compared to its 3-year average P/B ratio of 3.68 , the current P/B ratio is approximately -90.89% higher. Relative to its 5-year average P/B ratio of 5.27, the current P/B ratio is about -93.63% higher. Genmab A/S (GMAB) has a Forward Free Cash Flow (FCF) yield of approximately 6.81%. Compared to its 3-year average FCF yield of 5.41%, the current FCF yield is approximately 25.85% lower. Relative to its 5-year average FCF yield of 4.07% , the current FCF yield is about 67.48% lower.

0.34

P/B

Median3y

3.68

Median5y

5.27

6.90

FCF Yield

Median3y

5.41

Median5y

4.07

Competitors Valuation Multiple

The average P/S ratio for GMAB's competitors is , providing a benchmark for relative valuation. Genmab A/S Corp (GMAB) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 25.25%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of GMAB increased by 51.94% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 22.79 to 39.24.

The secondary factor is the Revenue Growth, contributed 25.25%to the performance.

Overall, the performance of GMAB in the past 1 year is driven by Margin Expansion. Which is more sustainable.

25.25%

816.00M → 1.02B

Revenue Growth

72.18%

22.79 → 39.24

Margin Expansion

-45.49%

2.32 → 1.26

P/E Change

51.94%

20.87 → 31.71

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Genmab A/S (GMAB) currently overvalued or undervalued?

What is Genmab A/S (GMAB) fair value?

GMAB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Genmab A/S (GMAB) is between 18.42 to 81.53 according to relative valuation methord.

How does GMAB's valuation metrics compare to the industry average?

What is the current P/B ratio for Genmab A/S (GMAB) as of Dec 18 2025?

As of Dec 18 2025, Genmab A/S (GMAB) has a P/B ratio of 0.34. This indicates that the market values GMAB at 0.34 times its book value.

What is the current FCF Yield for Genmab A/S (GMAB) as of Dec 18 2025?

As of Dec 18 2025, Genmab A/S (GMAB) has a FCF Yield of 6.81%. This means that for every dollar of Genmab A/S’s market capitalization, the company generates 6.81 cents in free cash flow.

What is the current Forward P/E ratio for Genmab A/S (GMAB) as of Dec 18 2025?

As of Dec 18 2025, Genmab A/S (GMAB) has a Forward P/E ratio of 21.62. This means the market is willing to pay $21.62 for every dollar of Genmab A/S’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Genmab A/S (GMAB) as of Dec 18 2025?

As of Dec 18 2025, Genmab A/S (GMAB) has a Forward P/S ratio of 4.64. This means the market is valuing GMAB at $4.64 for every dollar of expected revenue over the next 12 months.

GMAB Valuation

Overview

Forecast

Valuation

Earnings